Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Fig. 1

Best (minimum) percent change from baseline in sum of diameters (%) of target lesions. Baseline is defined as the last measurement prior to administration of the first dose of DS-8895a. Each vertical bar represents the best (minimum) percent change from baseline for an individual patient

Back to article page